vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and P10, Inc. (PX). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $81.0M, roughly 1.5× P10, Inc.). P10, Inc. runs the higher net margin — 11.7% vs 3.3%, a 8.3% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -4.7%). P10, Inc. produced more free cash flow last quarter ($18.1M vs $7.6M). Over the past eight quarters, P10, Inc.'s revenue compounded faster (10.7% CAGR vs 5.6%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
P10, Inc. is a global alternative investment management firm that offers a diversified portfolio of investment solutions spanning private equity, private credit, real assets and venture capital. It primarily caters to institutional clients including pension funds, endowments, foundations, and high-net-worth individuals across North America, Europe, and Asia Pacific.
NATR vs PX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $81.0M |
| Net Profit | $4.1M | $9.5M |
| Gross Margin | 72.5% | — |
| Operating Margin | 4.3% | 31.9% |
| Net Margin | 3.3% | 11.7% |
| Revenue YoY | 4.7% | -4.7% |
| Net Profit YoY | 1379.4% | 79.0% |
| EPS (diluted) | $0.23 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $81.0M | ||
| Q3 25 | $128.3M | $75.9M | ||
| Q2 25 | $114.8M | $72.7M | ||
| Q1 25 | $113.2M | $67.7M | ||
| Q4 24 | $118.2M | $85.0M | ||
| Q3 24 | $114.6M | $74.2M | ||
| Q2 24 | $110.6M | $71.1M | ||
| Q1 24 | $111.0M | $66.1M |
| Q4 25 | $4.1M | $9.5M | ||
| Q3 25 | $5.3M | $2.1M | ||
| Q2 25 | $5.3M | $3.4M | ||
| Q1 25 | $4.7M | $4.5M | ||
| Q4 24 | $-321.0K | $5.3M | ||
| Q3 24 | $4.3M | $1.4M | ||
| Q2 24 | $1.3M | $7.0M | ||
| Q1 24 | $2.3M | $5.0M |
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 71.4% | — | ||
| Q1 24 | 71.2% | — |
| Q4 25 | 4.3% | 31.9% | ||
| Q3 25 | 7.0% | 14.1% | ||
| Q2 25 | 3.7% | 24.4% | ||
| Q1 25 | 5.4% | 16.6% | ||
| Q4 24 | 3.8% | 26.9% | ||
| Q3 24 | 4.6% | 11.9% | ||
| Q2 24 | 5.1% | 23.7% | ||
| Q1 24 | 4.2% | 18.3% |
| Q4 25 | 3.3% | 11.7% | ||
| Q3 25 | 4.2% | 2.8% | ||
| Q2 25 | 4.6% | 4.7% | ||
| Q1 25 | 4.2% | 6.7% | ||
| Q4 24 | -0.3% | 6.2% | ||
| Q3 24 | 3.8% | 1.9% | ||
| Q2 24 | 1.2% | 9.8% | ||
| Q1 24 | 2.1% | 7.6% |
| Q4 25 | $0.23 | $0.08 | ||
| Q3 25 | $0.30 | $0.02 | ||
| Q2 25 | $0.28 | $0.03 | ||
| Q1 25 | $0.25 | $0.04 | ||
| Q4 24 | $-0.02 | $0.05 | ||
| Q3 24 | $0.23 | $0.01 | ||
| Q2 24 | $0.07 | $0.06 | ||
| Q1 24 | $0.12 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $28.2M |
| Total DebtLower is stronger | — | $373.2M |
| Stockholders' EquityBook value | $161.6M | $403.5M |
| Total Assets | $261.1M | $928.3M |
| Debt / EquityLower = less leverage | — | 0.93× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.9M | $28.2M | ||
| Q3 25 | $95.6M | $40.0M | ||
| Q2 25 | $81.3M | $33.4M | ||
| Q1 25 | $86.5M | $74.4M | ||
| Q4 24 | $84.7M | $67.5M | ||
| Q3 24 | $78.7M | $61.5M | ||
| Q2 24 | $68.7M | $31.2M | ||
| Q1 24 | $77.8M | $29.0M |
| Q4 25 | — | $373.2M | ||
| Q3 25 | — | $393.4M | ||
| Q2 25 | — | $373.0M | ||
| Q1 25 | — | $357.2M | ||
| Q4 24 | — | $319.8M | ||
| Q3 24 | — | $319.4M | ||
| Q2 24 | — | $300.6M | ||
| Q1 24 | $2.1M | $314.0M |
| Q4 25 | $161.6M | $403.5M | ||
| Q3 25 | $166.7M | $396.8M | ||
| Q2 25 | $163.7M | $388.9M | ||
| Q1 25 | $167.1M | $374.3M | ||
| Q4 24 | $161.0M | $386.9M | ||
| Q3 24 | $162.6M | $394.1M | ||
| Q2 24 | $156.4M | $396.9M | ||
| Q1 24 | $159.7M | $400.1M |
| Q4 25 | $261.1M | $928.3M | ||
| Q3 25 | $264.8M | $936.0M | ||
| Q2 25 | $254.9M | $932.2M | ||
| Q1 25 | $252.7M | $877.4M | ||
| Q4 24 | $240.9M | $869.3M | ||
| Q3 24 | $245.3M | $857.0M | ||
| Q2 24 | $235.8M | $823.2M | ||
| Q1 24 | $247.3M | $832.8M |
| Q4 25 | — | 0.93× | ||
| Q3 25 | — | 0.99× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 0.95× | ||
| Q4 24 | — | 0.83× | ||
| Q3 24 | — | 0.81× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | 0.01× | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $23.0M |
| Free Cash FlowOCF − Capex | $7.6M | $18.1M |
| FCF MarginFCF / Revenue | 6.1% | 22.3% |
| Capex IntensityCapex / Revenue | 1.9% | 6.0% |
| Cash ConversionOCF / Net Profit | 2.41× | 2.43× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $14.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $23.0M | ||
| Q3 25 | $18.5M | $-8.6M | ||
| Q2 25 | $4.3M | $13.4M | ||
| Q1 25 | $2.6M | $-4.7M | ||
| Q4 24 | $12.2M | $101.0M | ||
| Q3 24 | $9.6M | $27.5M | ||
| Q2 24 | $1.3M | $34.8M | ||
| Q1 24 | $2.2M | $11.0M |
| Q4 25 | $7.6M | $18.1M | ||
| Q3 25 | $16.8M | $-9.5M | ||
| Q2 25 | $3.0M | $11.6M | ||
| Q1 25 | $1.5M | $-6.0M | ||
| Q4 24 | $10.0M | $96.6M | ||
| Q3 24 | $7.9M | $25.2M | ||
| Q2 24 | $-2.0M | $33.9M | ||
| Q1 24 | $-1.5M | $10.7M |
| Q4 25 | 6.1% | 22.3% | ||
| Q3 25 | 13.1% | -12.6% | ||
| Q2 25 | 2.6% | 15.9% | ||
| Q1 25 | 1.3% | -8.9% | ||
| Q4 24 | 8.5% | 113.6% | ||
| Q3 24 | 6.9% | 34.0% | ||
| Q2 24 | -1.9% | 47.7% | ||
| Q1 24 | -1.4% | 16.2% |
| Q4 25 | 1.9% | 6.0% | ||
| Q3 25 | 1.3% | 1.2% | ||
| Q2 25 | 1.2% | 2.5% | ||
| Q1 25 | 1.0% | 1.9% | ||
| Q4 24 | 1.9% | 5.2% | ||
| Q3 24 | 1.5% | 3.0% | ||
| Q2 24 | 3.0% | 1.3% | ||
| Q1 24 | 3.3% | 0.4% |
| Q4 25 | 2.41× | 2.43× | ||
| Q3 25 | 3.46× | -4.01× | ||
| Q2 25 | 0.81× | 3.96× | ||
| Q1 25 | 0.55× | -1.05× | ||
| Q4 24 | — | 19.12× | ||
| Q3 24 | 2.21× | 19.54× | ||
| Q2 24 | 0.97× | 4.98× | ||
| Q1 24 | 0.94× | 2.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
PX
| Management Fees | $78.1M | 96% |
| Advisory Fees | $1.8M | 2% |
